Back to list

ARPANSA authorises ANSTO Nuclear Medicine facility to return to routine operation

Wednesday 01, Apr 2020

31 March 2020

On 27 March 2020, the CEO of ARPANSA, Dr Carl-Magnus Larsson, removed a licence condition from the ANSTO Nuclear Medicine (ANM) facility, allowing it to return to routine operation.

Following a contamination event on 21 June 2019, ANSTO suspended production of molybdenum-99 (Mo-99).  

On 5 July 2019, the CEO of ARPANSA granted approval to resume operation subject to a licence condition restricting the production level of Mo-99. The licence condition required ANSTO to provide evidence of safe operation, satisfactory training records, evidence of appropriate management of conflicting production and safety imperatives, satisfactory staffing levels and rectification of safety significant issues resulting from the June 2019 contamination event.

To read the full statement, please visit